ArticleApplied and environmental microbiology2014
Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice.
Article in Applied and environmental microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 102 citations in OpenAlex.
- Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoEJournal of cellular and molecular medicine · 2026Article
- Probiotics in atherosclerosis: mechanisms, efficacy and future directions - a review study.Frontiers in immunology · 2026Review
- Article
- Review
- Gut microbiota: a novel strategy affecting atherosclerosis.Microbiology spectrum · 2025Review
- Potential effects of probiotics on atherosclerosis.Microbiome research reports · 2025Review
- Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
- HFD aggravated the arthritis and atherosclerosis by altering the intestinal status and gut microbiota.Molecular medicine (Cambridge, Mass.) · 2024Article
- Intestinal Insights: The Gut Microbiome's Role in Atherosclerotic Disease: A Narrative Review.Microorganisms · 2024Review
- Targeting Gut Microbiota with Probiotics and Phenolic Compounds in the Treatment of Atherosclerosis: A Comprehensive Review.Foods (Basel, Switzerland) · 2024Review
- Safety Evaluation of a Novel Potentially Probiotic Limosilactobacillus fermentum in Rats.Probiotics and antimicrobial proteins · 2024Article
- Impact of Probiotic Lactiplantibacillus plantarum ATCC 14917 on atherosclerotic plaque and its mechanism.World journal of microbiology & biotechnology · 2024Article
- The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.International journal of molecular sciences · 2023Review
- Gut microbial change after administration ofFrontiers in endocrinology · 2023Article
- Mitochondria as novel mediators linking gut microbiota to atherosclerosis that is ameliorated by herbal medicine: A review.Frontiers in pharmacology · 2023Review
- Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State.Life (Basel, Switzerland) · 2022Review
- The Functional Roles ofJournal of microbiology and biotechnology · 2022Review
- Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases.Foods (Basel, Switzerland) · 2022Review
- Tackling Atherosclerosis via Selected Nutrition.International journal of molecular sciences · 2022Review
- Probiotics: Protecting Our Health from the Gut.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to investigate the effect of Lactobacillus acidophilus ATCC 4356 on the development of atherosclerosis in apolipoprotein E-knockout (ApoE(-/-)) mice. Eight-week-old ApoE(-/-) mice were fed a Western diet with or without L. acidophilus ATCC 4356 daily for 16 weeks. L. acidophilus ATCC 4356 protected ApoE(-/-) mice from atherosclerosis by reducing their plasma cholesterol levels from 923 ± 44 to 581 ± 18 mg/dl, likely via a marked decrease in cholesterol absorption caused by modulation of Niemann-Pick C1-like 1 (NPC1L1). In addition, suppression of cholesterol absorption induced reverse cholesterol transport (RCT) in macrophages through the peroxisome proliferator-activated receptor/liver X receptor (PPAR/LXR) pathway. Fecal lactobacillus and bifidobacterium counts were significantly (P < 0.05) higher in the L. acidophilus ATCC 4356 treatment groups than in the control groups. Furthermore, L. acidophilus ATCC 4356 was detected in the rat small intestine, colon, and feces during the feeding trial. The bacterial levels remained high even after the administration of lactic acid bacteria had been stopped for 2 weeks. These results suggest that administration of L. acidophilus ATCC 4356 can protect against atherosclerosis through the inhibition of intestinal cholesterol absorption. Therefore, L. acidophilus ATCC 4356 may be a potential therapeutic material for preventing the progression of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.